A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a (14)C‐Microtracer Approach

Zimlovisertib (PF‐06650833) is a selective, reversible inhibitor of interleukin‐1 receptor‐associated kinase 4 (IRAK4) with anti‐inflammatory effects. This phase 1, open‐label, fixed‐sequence, two‐period, single‐dose study aimed to evaluate the mass balance and excretion rate of zimlovisertib in hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ravi Shankar P., Dowty, Martin E., Salganik, Mikhail, Brodfuehrer, Joanne I., Walker, Gregory S., Sharma, Raman, Beebe, Jean S., Danto, Spencer I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322294/
https://www.ncbi.nlm.nih.gov/pubmed/35506501
http://dx.doi.org/10.1002/cpdd.1109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322294/
https://www.ncbi.nlm.nih.gov/pubmed/35506501
http://dx.doi.org/10.1002/cpdd.1109

Ejemplares similares